InpharmD™





One touch literature search.

So you can spend more time with patients

Ask any clinical question, receive a curated response.

Get Started Free

Trusted by 10,000+ clinical pharmacists.

                           

Play Circle

Learn about InpharmD™ in under 90 seconds

What is InpharmD™?


Literature searching is tedious. InpharmD™ is here to help.

Clinical pharmacists can ask any question, anytime, from anywhere, and we’ll perform a custom literature search.

(And a 32% chance it’s already been asked.)


More than 30 of the world's best health systems hire an InpharmD™ virtual DI pharmacist, yielding:


141,798

Clinical Pharmacist Hours Saved

4x +

ROI

100%

Customer Satisfaction Rate

This is how InpharmD™ transforms LITERATURE.

What's Being Asked...

Is there literature comparing efficacy and safety between the CGRP Receptor Antagonists?
What is best practice for dosing albumin in hepatology?
What are the best ways to decrease distractions in an inpatient pharmacy department?
What is the long-term data of topiramate's effect on bone density
Is there literature supporting dose rounding of Thymoglobulin to the nearest vial size?

What would you like to ask InpharmD™?

InpharmD's Answer GPT's Answer

Author:Rachel Deryck, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Available evidence comparing calcitonin gene-related peptide (CGRP) receptor antagonists is largely derived from meta-analyses and indirect comparisons rather than direct head-to-head randomized trials. However, data from these analyses consistently demonstrate that both gepants (e.g., rimegepant, ubrogepant, zavegepant) for acute treatment and monoclonal antibodies (e.g., erenumab, fremanezumab, galcanezumab, eptinezumab) for prevention are superior to placebo, with generally similar efficac...

A 2024 systematic review and network meta analysis (NMA) of 18 randomized controlled trials (RCTs) including 22,429 patients compared Lasmiditan, Rimegepant, Ubrogepant, and Zavegepant for acute migraine treatment. All agents were superior to placebo. For pain freedom at 2 hours, lasmiditan 100 mg (risk ratio [RR] 1.54; 95% confidence interval [CI] 1.21 to 1.99), lasmiditan 200 mg (RR 1.85; CI 1.46 to 2.40), rimegepant 75 mg (RR 1.82; CI 1.30 to 2.55), and ubrogepant 25 to 100 mg were all effective, with ubrogepant 100 mg ranking highest. For pain relief at 2 hours, lasmiditan 100 mg (RR 1.44; CI 1.34 to 1.55) and 200 mg (RR 1.43; CI 1.33 to 1.54) ranked highest and were superior to lower dose ubrogepant and zavegepant. For most bothersome symptom freedom at 2 hours, rimegepant 75 mg (RR 1.40, CI 1.17 to 1.68) and ubrogepant 50 mg (RR 1.40; CI 1.11 to 1.78) ranked highest. For sustained pain relief at 24 hours, all gepants were effective, including rimegepant, ubrogepant 25 to 100 m...

READ MORE→

A search of the published medical literature revealed 1 study investigating the researchable question:

Is there literature comparing efficacy and safety between the CGRP Receptor Antagonists?

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

[1] Deng X, Zhou L, Liang C, et al. Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials. J Headache Pain. 2024;25(1):16. Published 2024 Feb 5. doi:10.1186/s10194-024-01723-4
[2] Haridas MP, Tripathy A, Maiti R, Srinivasan A. Efficacy and safety of anti-cgrp monoclonal antibodies in prevention of chronic migraine: a bayesian network meta-analysis. Clin Psychopharmacol Neurosci. 2024;22(1):23-32. doi:10.9758/cpn.23.1109
[3] Asawavichienjinda T, Sathitratanacheewin S, Chokesuwattanaskul R. "Wearing-off" efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials. Cephalalgia. 2023;43(4):3331024231161261. doi:10.1177/03331024231161261
[4] Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023;43(4):3331024231159366. doi:10.1177/03331024231159366
[5] Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis. Cephalalgia. 2023;43(3):3331024231152169. doi:10.1177/03331024231152169
[6] Lee S, Staatz CE, Han N, Baek IH. Safety evaluation of oral calcitonin-gene-related peptide receptor antagonists in patients with acute migraine: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2022;78(9):1365-1376. doi:10.1007/s00228-022-03347-6
[7] Masoud AT, Hasan MT, Sayed A, et al. Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials. J Neurol Sci. 2021;427:117505. doi:10.1016/j.jns.2021.117505
[8] Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score. CNS Drugs. 2022;36(2):191-202. doi:10.1007/s40263-021-00893-y

InpharmD's Answer GPT's Answer

Author:zophia@inpharmd.com, PharmD, BCPS + InpharmD™ AI LEARN MORE 

According to societal guidelines, best practice for albumin dosing in hepatology is indication-specific, with use focused on preventing circulatory dysfunction and renal injury in decompensated cirrhosis rather than correcting serum albumin levels. In large-volume paracentesis (LVP), guidelines recommend albumin when >5 L of ascites is removed at approximately 6-8 g per liter of ascites drained, with little to no routine requirement for smaller-volume procedures unless high-risk features are ...

The 2021 American Association for the Study of Liver Diseases (AASLD) practice guidance on ascites, spontaneous bacterial peritonitis (SBP), and hepatorenal syndrome (HRS) emphasizes albumin as a therapeutic intervention in decompensated cirrhosis, used to modify clinically meaningful outcomes rather than to correct serum albumin levels. Albumin is described as a multifunctional protein with oncotic, anti-inflammatory, antioxidant, and endothelial-stabilizing effects, and its clinical use is directed toward the prevention and treatment of circulatory dysfunction and renal injury. [1] In patients with tense or grade 3 ascites, large-volume paracentesis (LVP) is recommended as first-line therapy, with intravenous (IV) hyperoncotic human albumin administered to prevent postparacentesis circulatory dysfunction (PPCD). Albumin is particularly indicated when more than 5 L of ascitic fluid are removed, since smaller-volume paracentesis is not typically associated with clinically signif...

READ MORE→

A search of the published medical literature revealed 0 studies investigating the researchable question:

What is best practice for dosing albumin in hepatology?

Level of evidence
A - Multiple high-quality studies with consistent results  

READ MORE→

[1] Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-1048. doi:10.1002/hep.31884
[2] Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):1651-1653. doi:10.1002/hep.26359
[3] Management of adult patients with ascites due to cirrhosis: AASLD practice guideline update 2012. Accessed April 28, 2026. https://apps.sbgh.mb.ca/labmanual/test/loadDocumentPdf?documentId=1321
[4] Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021;70(1):9-29. doi:10.1136/gutjnl-2020-321790
[5] Wong YJ, Kumar R, Chua YJJ, Ang TL. Long-term albumin infusion in decompensated cirrhosis: A review of current literature. World J Hepatol. 2021;13(4):421-432. doi:10.4254/wjh.v13.i4.421

InpharmD's Answer GPT's Answer

Author:zophia@inpharmd.com, PharmD, BCPS + InpharmD™ AI LEARN MORE 

There are limited data describing strategies to decrease distractions and interruptions in an inpatient pharmacy setting. Available literature consistently identifies frequent interruptions during medication order review, verification, preparation, and dispensing as contributors to reduced efficiency and increased risk of medication errors. Across observational and interventional studies, common sources of disruption include telephone calls, order status inquiries, missing medications, collea...

Distractions and interruptions are common in healthcare settings and pose a significant threat to human performance and patient safety, particularly during medication-related tasks. A distraction occurs when attention is diverted from a primary task, while an interruption occurs when a task is stopped to address another activity with the intention of returning later. In modern practice environments, multitasking is often expected, and pharmacists, technicians, and nurses may be distracted or interrupted as frequently as every two minutes. Sources of distractions may be voluntary, such as multitasking, checking emails or mobile devices, and socializing, or involuntary, such as hunger, fatigue, or stress. Interruptions are typically external and include phone calls, patient questions, conversations among colleagues, electronic health record alerts, and device alarms. These disruptions can impair concentration, increase cognitive load, contribute to forgetfulness, and lead to medicatio...

READ MORE→

A search of the published medical literature revealed 0 studies investigating the researchable question:

What are the best ways to decrease distractions in an inpatient pharmacy department?

Level of evidence
B - One high-quality study or multiple studies with limitations  

READ MORE→

[1] Institute for Safe Medication Practices (ISMP). Minimizing distractions and interruptions during medication safety tasks. ISMP Medication Safety Alert! Acute Care. 2023;28(20):1-3.
[2] Christiano D, SingleCare. How techs can avoid distractions in the pharmacy. The Checkup. https://www.singlecare.com/blog/interruptions-and-distractions-pharmacy/. Published January 22, 2026.
[3] McGinley P. The Impact of Interruptions and Distractions on Hospital Pharmacies: A Review with Recommendations - Patient Safety & Quality Healthcare. Patient Safety & Quality Healthcare. https://www.psqh.com/news/the-impact-of-interruptions-and-distractions-on-hospital-pharmacies-a-review-with-recommendations/. Published July 8, 2016.
[4] Raimbault M, Guérin A, Caron E, Lebel D, Bussières JF. Identifying and reducing distractions and interruptions in a pharmacy department. Am J Health Syst Pharm. 2013;70(3):186-190. doi:10.2146/ajhp120344
[5] Binobaid S, Almeziny M, Fan IS. Using an integrated information system to reduce interruptions and the number of non-relevant contacts in the inpatient pharmacy at tertiary hospital. Saudi Pharm J. 2017;25(5):760-769. doi:10.1016/j.jsps.2016.11.005
[6] Kojima T, Kinoshita N, Kitamura H, et al. Effect of improvement measures in reducing interruptions in a Japanese hospital pharmacy using a synthetic approach based on resilience engineering and systems thinking. BMC Health Serv Res. 2023;23(1):331. Published 2023 Apr 3. doi:10.1186/s12913-023-09346-2

InpharmD's Answer GPT's Answer

Author:Naveed Aijaz, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Long-term data suggest that topiramate is associated with adverse effects on bone health, primarily through suppression of bone formation. Evidence indicates a measurable increase in fracture risk (approximately 39%) among users, supporting concerns about reduced bone mineral density (BMD) over time. Additional studies have shown that factors such as prolonged therapy duration, low body mass index (BMI), older age and polytherapy further increase osteoporosis risk. Given these findings, regul...

A 2014 systematic review and meta-analysis synthesized data to evaluate the association between antiepileptic drug (AED) use and fracture risk. The meta-analysis utilized a random-effects model to pool results and assess the strength of the association between AED use and fracture risk. Results from the analysis demonstrated a significant increase in fracture risk among AED users, with a relative risk (RR) of 1.86 (95% confidence interval [CI] 1.62–2.12). A notable finding was that both liver enzyme-inducing AEDs (LEI AEDs) and non-LEI AEDs were associated with elevated fracture risk, although the risk was more pronounced for LEI AEDs (RR = 1.18; 95% CI 1.11–1.25). Specific AEDs such as phenobarbiturate (PB), topiramate (TPM), and phenytoin (PHT) were highlighted due to their significant associations with increased fracture risk, showing increases of 78%, 39%, and 70% respectively. The meta-analysis thus underscores a robust link between AED use and heightened fracture risk, particu...

READ MORE→

A search of the published medical literature revealed 2 studies investigating the researchable question:

What is the long-term data of topiramate's effect on bone density

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

[1] Shen C, Chen F, Zhang Y, Guo Y, Ding M. Association between use of antiepileptic drugs and fracture risk: a systematic review and meta-analysis. Bone. 2014;64:246-253. doi:10.1016/j.bone.2014.04.018
[2] Vestergaard P. Effects of antiepileptic drugs on bone health and growth potential in children with epilepsy. Paediatr Drugs. 2015;17(2):141-150. doi:10.1007/s40272-014-0115-z
[3] Baddoo DR, Mills AA, Kullab RB, Al-Mashat H, Andersen NB, Jørgensen NR, Diemar SS. Metabolic bone disease in patients with epilepsy and the use of antiepileptic drugs: Insight from a Danish cross-sectional study. Seizure. 2021;87:88-94. doi:10.1016/j.seizure.2021.02.013

InpharmD's Answer GPT's Answer

Author:azkaa@inpharmd.com, PharmD, BCPS + InpharmD™ AI LEARN MORE 

While the literature appears scattered, several retrospective studies and a 2021 review indicate that rounding thymoglobulin doses to the nearest 25 mg vial is a common practice employed to reduce waste. The literature shows mixed outcomes: two studies found that modest dose variations from rounding and capping did not increase rejection risk when combined with triple maintenance immunosuppression, while a third study reported that rounding down was associated with significantly higher biopsy...

A 2021 review on transplant stewardship discusses rATG dose rounding and capping as cost-reduction strategies that, despite being relatively common in practice, carry limited supporting evidence and are not endorsed by FDA labeling. Two retrospective studies were highlighted. The first examined 242 adult kidney transplant recipients undergoing early steroid withdrawal who received four doses of rATG 1.5 mg/kg (total body weight), rounded to the nearest 25 mg vial and capped at a single dose of 150 mg; patients with cumulative doses ≥6 mg/kg had significantly lower biopsy-proven acute rejection (BPAR) compared to those receiving <6 mg/kg (11% vs. 21.2%, p < 0.042), but no differences in patient/graft survival, renal function, leukopenia, or thrombocytopenia were observed. The second study involved 261 recipients with continued steroids, targeting a total cumulative dose of 5 mg/kg but capped at 500 mg, and found no difference in BPAR (8.9% vs. 8.7%) or other clinical endpoints betwee...

READ MORE→

A search of the published medical literature revealed 3 studies investigating the researchable question:

Is there literature supporting dose rounding of Thymoglobulin to the nearest vial size?

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

[1] Jorgenson MR, Descourouez JL, Brady BL, et al. A call for transplant stewardship: The need for expanded evidence-based evaluation of induction and biologic-based cost-saving strategies in kidney transplantation and beyond. Clin Transplant. 2021;35(9):e14372. doi:10.1111/ctr.14372

Why choose InpharmD™?

Find answers, not documents.

Before InpharmD™


BeforeTime
Your team spends hours per week cobbling together literature from different studies, many behind paywalls, leaving little time for action.
BeforeTime
TI opportunities are discovered (or presented by third parties) months after the fact, resulting in costly missed savings.
BeforeTime
Decisions may be made without a complete picture, or pushed out while gathering consensus.

After InpharmD™


BeforeTime
InpharmD™ delivers customized, actionable drug information in real time, so you can focus on execution.
BeforeTime
Your team stays informed immediately when new data emerges or prices change, and you’ll always be the first to know when any changes impact your formulary.
BeforeTime
With InpharmD™, your team can make faster, more informed decisions and move forward with confidence.

What Clinical Pharmacists Are Saying...


     

Assists in our research and is a great way or us to get an answer to a medical question without spending an average of 2 hours researching UptoDate or PubMed ourselves.


  Jordan C., PharmD, New Jersey

     

Huge time saver with thorough responses.


  Jane D., PharmD, Georgia

     

I’d never heard of a DI pharmacist before, now I have one. In. My. Pocket. Amazing!


     

Holy Shhh. Cow! Holy Cow! These summaries are beautiful.


  Jane D., PharmD, Georgia

     

I just want to say: This is such a brilliant idea! You people are genius.


     

OH MY GOD WHERE HAVE YOU BEEN ALL MY LIFE!


     

I can’t tell you how much time I spend literature searching. And how I CANNOT STAND PAYWALLS. THIS IS UNBELIEVABLE!! (covers face for sec) thank you, thank you, thank you!


     

So they’re basically connecting academic researchers with front line providers and then automating everything. It’s simply brilliant.


     

The clinical pharmacist was our secret weapon anyway. (Smiles wryly) This pharmacist AI seems superhuman. I’m just blown away, honestly. (Looks at camera somberly.)


     

It’s an ENTIRE DI DEPARTMENT, that lives in Epic. Give me a second. I’m just having a hard time wrapping my head around that.


     

Sorry just give me a second, my mind is blown.


     

Stop reading and just download the app already! I’ve tried all of them. This is by far the most advanced, best-in-class.


What would you like to ask InpharmD™?

Sign up for a free trial & start right away.

Get Started Free